Health AI Central
Share:
Peer-Reviewed Publication
Oral Oncol2026;178108006.July 1, 2026Journal Article

Impact of metastasis-directed therapy for metachronous thoracic metastases following definitive (chemo)radiotherapy in p16-positive head and neck squamous cell carcinoma.

Sophia Ly1, Alexander Rühle2, Scott Bratman3, John Cho4, Ali Hosni5, Ezra Hahn6, John Kim7, Andrew McPartlin8, Jolie Ringash9, Brian O'Sullivan10, C Jillian Tsai11, John Waldron12, David Goldstein13, Enrique Sanz-Garcia14, Anna Spreafico15, Jie Su16, Li Tong17, Ilan Weinreb18, Shao Hui Huang19, Andrew Hope20
1Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Sophia.ly@uqconnect.edu.au.
2Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Alexander.Ruhle@uhn.ca.
3Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Scott.Bratman@uhn.ca.
4Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: John.Cho@uhn.ca.
5Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Ali.Hosni@uhn.ca.
6Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Ezra.Hahn@uhn.ca.
7Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: John.Kim@uhn.ca.
8Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Andrew.McPartlin@uhn.ca.
9Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Jolie.Ringash@uhn.ca.
10Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada; Department of Otolaryngology - Head & Neck Surgery, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Brian.Osullivan@uhn.ca.
11Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Jillian.Tsai@uhn.ca.
12Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada; Department of Otolaryngology - Head & Neck Surgery, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: John.Waldron@uhn.ca.
13Department of Otolaryngology - Head & Neck Surgery, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: David.Goldstein@uhn.ca.
14Division of Medical Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Enrique.SanzGarcia@uhn.ca.
15Division of Medical Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Anna.Spreafico@uhn.ca.
16Department of Biostatistics, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Susie.Su@uhn.ca.
17Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Li.Tong@uhn.ca.
18Department of Pathology, University Health Network, Toronto, Canada. Electronic address: Ilan.Weinreb@uhn.ca.
19Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Shaohui.huang@uhn.ca.
20Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada. Electronic address: Andrew.Hope@uhn.ca.
PubMed DOI

Abstract

OBJECTIVES: To report oncologic outcomes after metastasis-directed treatment (MDT) for metachronous thoracic metastases following definitive (chemo-)radiotherapy in p16-positive head and neck squamous cell carcinoma (HNSCC). METHODS: We reviewed all p16-positive HNSCC patients who developed metachronous thoracic metastases after definitive (chemo)radiotherapy (2003-2021). Metastatic disease was f…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.